BioForce Nanosciences Holdings(BFNH)
$6.70-0.26 (-3.74%)
BFNH
BioForce Nanosciences Holdings financials statements
$6.70
At close:-0.26 (-3.74%)
BioForce Nanosciences Holdings (BFNH) Ratios
11 Followers
BioForce Nanosciences Holdings Ratios
BFNH's free cash flow for Q3 2026 was $-94.79K. For the 2026 fiscal year, BFNH's free cash flow was increased by $0.00 and operating cash flow was $-94.79K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Quick Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Solvency Ratio | -2.09 | -0.21 | 0.00 | -0.36 | -0.57 |
| Operating Cash Flow Ratio | -0.11 | -0.03 | -0.03 | -0.05 | -0.09 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -0.22 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -618.54K | $ -2.30M | $ -1.82M | $ -1.35M | $ -861.86K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 317.98 | 345.93 | 237.19 | 10.42 |
| Debt-to-Equity Ratio | 0.00 | -0.12 | -0.12 | -0.13 | -0.13 |
| Debt-to-Capital Ratio | 0.00 | -0.14 | -0.14 | -0.15 | -0.16 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
| Debt Service Coverage Ratio | 0.00 | -1.79 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 |
| Net Debt to EBITDA | 0.00 | -0.56 | 0.00 | -0.36 | -0.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 263.69% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Return on Assets (ROA) | -164370.36% | -56895.24% | -73973.82% | -66146.32% | -4503.86% |
| Return on Equity (ROE) | 208.87% | 21.31% | 25.94% | 36.04% | 58.24% |
| Return on Capital Employed (ROCE) | 79.21% | 21.31% | 25.94% | 36.04% | 58.24% |
| Return on Invested Capital (ROIC) | 79.21% | 24.19% | 25.94% | 36.04% | 58.24% |
| Return on Tangible Assets | -164370.36% | -56895.24% | -73973.82% | -66146.32% | -4503.86% |
| Earnings Yield | -6.71% | -4.91% | -0.80% | -0.83% | -1.43% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | -0.22 | -0.21 | -0.39 | -0.67 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -0.34% | -0.61% | -0.08% | -0.12% | -0.22% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -14.91 | -20.33 | -124.67 | -119.98 | -69.98 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -31.14 | -4.34 | -32.34 | -43.24 | -40.76 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -295.63 | -163.20 | -1259.82 | -851.76 | -451.65 |
| Price-to-Operating Cash Flow Ratio | -295.63 | -163.20 | -1259.82 | -851.76 | -451.65 |
| Price-to-Earnings Growth (PEG) Ratio | -0.11 | -4.68 | 41.39 | 41.03 | 0.70 |
| Enterprise Value Multiple | -39.31 | -20.94 | 0.00 | -120.33 | -70.19 |
| Enterprise Value | 19.26M | 10.27M | 59.06M | 58.42M | 35.23M |
| EV to EBITDA | -39.31 | -20.94 | 0.00 | -120.33 | -70.19 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -295.62 | -167.67 | -1264.53 | -854.29 | -453.01 |
| EV to Operating Cash Flow | -295.62 | -167.67 | -1264.53 | -854.29 | -453.01 |
| Tangible Book Value Per Share | -0.02 | -0.08 | -0.06 | -0.05 | -0.03 |
| Shareholders’ Equity Per Share | -0.02 | -0.08 | -0.06 | -0.05 | -0.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.04 | -0.02 | -0.02 | -0.02 | -0.02 |
| Tax Burden | 2.64 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.05 | 0.12 | 0.10 | 0.14 | 0.15 |
Currency in USD
